Cipla recalls 4,800 bottles of anti-HIV tablets from US

As per the latest Enforcement Report by the United States Food and Drug Administration (USFDA), the reason for the recall of the bottles is 'failed dissolution specifications'.

Cipla recalls 4,800 bottles of anti-HIV tablets from US
Cipla is recalling 4,800 bottles of Nevirapine extended release tablets used for the treatment of human immunodeficiency virus (HIV) from the American market, Image source: Reuters
Written By: PTI
Updated: Sun, Dec 30, 2018
11:58 am
New Delhi, PTI
RELATED NEWS
Stock Market: Sensex, Nifty trade range-bound on weak global cues; Cipla, ITI, RBL Bank stocks crash Stock Market: Sensex, Nifty trade range-bound on weak global cues; Cipla, ITI, RBL Bank stocks crash
Stocks in Focus on January 23: ITI, Cipla to Telecom shares; here are expected 5 Newsmakers of the Day Stocks in Focus on January 23: ITI, Cipla to Telecom shares; here are expected 5 Newsmakers of the Day

Drug major Cipla is recalling 4,800 bottles of Nevirapine extended release tablets used for the treatment of human immunodeficiency virus (HIV) from the American market, according to a report by the US health regulator. 

As per the latest Enforcement Report by the United States Food and Drug Administration (USFDA), the reason for the recall of the bottles is 'failed dissolution specifications'.

Nevirapine extended release tablets, 400 mg in the 30-count bottle have been manufactured by Cipla at its Goa facility for Cipla USA Inc, it added.

The US health regulator has not yet classified the voluntary recall by the company, the report said.